Showing results (51-60 of 72) with videos related to
Sort By:
Pageof 8
Journal of the National Cancer Institute|August 22, 2025
The impact of eligibility criteria on KRASG12C inhibitor trials in patients with NSCLCMargaux Wooster, Michael May, Prashasti Agrawal, et al.The Lancet. Oncology|May 11, 2020
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trialCatherine A Shu, Justin F Gainor, Mark M Awad, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 14, 2023
CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief ReportDong-Wan Kim, Sang-We Kim, D Ross Camidge, et al.Journal of Personalized Medicine|May 27, 2025
Central Nervous System Metastases from Primary Lung Carcinoma: Significance of RNA Fusion Testing and Early Versus Late MetastasesMichelle Garlin Politis, Mahesh Mansukhani, Benjamin O Herzberg, et al.Lung Cancer (Amsterdam, Netherlands)|March 3, 2023
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS studyKeunchil Park, Joshua K Sabari, Eric B Haura, et al.Journal for Immunotherapy of Cancer|December 25, 2024
Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findingsBrian S Henick, Peter D Koch, Justin F Gainor, et al.Cancer Discovery|January 26, 2022
Targeting S100A9-ALDH1A1-Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung CancerAnup Kumar Biswas, Seoyoung Han, Yifan Tai, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2024
Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC)Luke R G Pike, Emily Miao, Lillian A Boe, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 28, 2023
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLCKaiwen Wang, Robyn Du, Nathaniel J Myall, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2018
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancersJ K Sabari, G C Leonardi, C A Shu, et al.Pageof 8